Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of “Hold” from Analysts

Invivyd, Inc. (NASDAQ:IVVD) has received an average rating of “Hold” from the six brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $8.00.

A number of research analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Invivyd in a report on Thursday, February 26th. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th.

Insider Buying and Selling at Invivyd

In related news, insider Jill Andersen sold 34,939 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $55,203.62. Following the completion of the transaction, the insider owned 181,736 shares in the company, valued at approximately $287,142.88. The trade was a 16.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO William E. Duke sold 20,964 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $33,123.12. Following the completion of the transaction, the chief financial officer directly owned 107,717 shares in the company, valued at $170,192.86. This trade represents a 16.29% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 227,172 shares of company stock worth $354,534. 25.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Invivyd

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in Invivyd during the fourth quarter worth approximately $500,000. Invesco Ltd. raised its holdings in Invivyd by 67.6% during the fourth quarter. Invesco Ltd. now owns 293,580 shares of the company’s stock worth $725,000 after purchasing an additional 118,411 shares in the last quarter. Ikarian Capital LLC lifted its position in shares of Invivyd by 27.8% during the 4th quarter. Ikarian Capital LLC now owns 2,656,570 shares of the company’s stock worth $6,562,000 after buying an additional 577,864 shares during the last quarter. Virtus Investment Advisers LLC acquired a new position in shares of Invivyd in the 4th quarter valued at $283,000. Finally, Quadrature Capital Ltd boosted its holdings in shares of Invivyd by 98.3% in the 4th quarter. Quadrature Capital Ltd now owns 91,241 shares of the company’s stock valued at $225,000 after buying an additional 45,229 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Stock Up 1.8%

Shares of IVVD stock opened at $1.74 on Friday. The firm has a 50 day moving average of $2.01 and a two-hundred day moving average of $1.81. The stock has a market capitalization of $405.63 million, a PE ratio of -3.70 and a beta of 0.61. Invivyd has a 52 week low of $0.46 and a 52 week high of $3.07.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.